The Carcinoid Cancer Foundation in White Plains, New York has awarded a grant of more than $65,000.00 to Stanford University in California to expand access to its Gallium-68 (Ga-68) DOTA-TATE PET/CT program for carcinoid and neuroendocrine tumor (NET) patients with somatostatin receptor positive tumors. Click here to read more.

UCSF has received approval for their Ga68 Pet/CT study and are now accepting patients. Click here to read more.

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Click here to download the press release.

Lexicon has added an additional trial for those that did not meet the inclusion criteria of the Telestar trial.Telecast trialis now open at Stanford. Both trials are for those that have carcinoid symptoms who are refractory to, or could not tolerate somatostatin analog therapy. Lexicon includes travel support to those who do not live near a participating center but who otherwise qualify for the study.

August 2nd, 2014 - NorCal CarciNet Community Bi-monthly Meeting

On Saturday, August 2nd, 2014 from 1-4pm we will have our regular meeting at the Cancer Support Community (CSC) in Walnut Creek.

Dr. Edda Gomez-Panzani, Ipsen's Vice President, Clinical Sciences - Neuroendocrinologywill be joining us. She will talk to us about the Clarinet clinical trial that was published last year, and give an overview talk about cancer.

On Saturday, August 2nd, 2014 from 1-4pm we will have our regular meeting at the Cancer Support Community (CSC) in Walnut Creek.

Dr. Edda Gomez-Panzani, Ipsen's Vice President, Clinical Sciences - Neuroendocrinologywill be joining us. She will talk to us about the Clarinet clinical trial that was published last year, and give an overview talk about cancer and the challenges of diagnosing NETs. See the In the News section below for more Ipsen related news. This presentation will not be recorded.

A year ago we asked the NorCal CarciNet Community to join with the board and write a letter to the DOE on their proposal to exit the Ge68 market. Ge68 is required for Gallium 68 (ga68) production which when used with a PET/CT produces improved imaging for those with neuroendocine tumors. In the year since our letter Stanford, UCLA, and the NIH have joined the University of Iowa and Vanderbilt as centers that offer the Ga68 PET/CT to NET patients. On April 2nd the DOE issued a notice that the DOE will continue to supply Ge68 for Gallium 68 (Ga68) generators. This is good news for the NET community as it will insure that the material needed to produce Ga68 for PET/CT will continue to be available as additional facilities start offering Ga68 PET/CT scans. The DOE is asking for additional comments on this subject before May 1, 2014 and we plan on providing additional comments which we will share with our community prior to that date. Thank you for your support on this issue.

This Ga68 PET/CT and PRRT trial will assess the potential viability of 68 Ga-DOTA-JR11 and 177 Lu-DOTA-JR11 as a pair of diagnostic and therapeutic radiopeptides for neuroendocrine tumor patients. To improve effectiveness while reducing side effects, the Sloan Kettering team will employ a somatostatin antagonists (DOTA-JR11.) Based on preclinical data, Sloan Kettering believes that somatostatin receptor antagonists can be more effective and generate fewer side effects than the substances that are currently being used to treat patients with PRRT. To read more about this announcement click here.

2014 National NET Patient Conference Early Registration Ends April 30.

The 2014 National NET Patient conference is in Charlotte NC on Thursday, September 18, 2014 through Saturday, September 20, 2014. A special Lungnoid meeting will be help on Sunday, September 21, 2014. Early registration ($100) ends on April 30, 2014. For more information on the conference and to register please visit the registration site.